US · VIVS
VivoSim Labs, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- vivosim.ai
Price · as of 2025-03-31
$1.44
Market cap 5.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $301.08 | +20,808.33% |
| Intrinsic Value(DCF) | $0.74 | -48.61% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $960.00 | ||||
| 2014 | $1,852.80 | $813.87 | $81.19 | $0.00 | $4,859.68 |
| 2015 | $1,209.60 | $486.45 | $67.04 | $0.00 | $0.00 |
| 2016 | $744.00 | $300.63 | $24,770.53 | $0.00 | $0.00 |
| 2017 | $645.60 | $272.93 | $4,817,506.19 | $0.00 | $0.00 |
| 2018 | $331.20 | $137.18 | $2,433.31 | $0.00 | $0.00 |
| 2019 | $110.40 | $540.30 | $20.37 | $0.00 | $1,287.76 |
| 2020 | $160.80 | $510.18 | $6.78 | $0.00 | $679.63 |
| 2021 | $103.08 | $138.48 | |||
| 2022 | $25.08 | $28.22 | $0.00 | ||
| 2023 | $20.88 | $42.78 | $0.00 | $0.00 | $1,521.07 |
| 2024 | $11.52 | $17.28 | $0.00 | $0.00 | $1,143.53 |
| 2025 | $1.84 | $301.08 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates VivoSim Labs, Inc.'s (VIVS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $301.08
- Current price
- $1.44
- AI upside
- +20,808.33%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.74
-48.61% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VIVS | VivoSim Labs, Inc. | $1.44 | 5.66M | +20,808% | -49% | — | — | -1.08 | 0.26 | 18.70 | 3.47 | — | 0.26 | 96.53% | -8761.11% | -1727.78% | -35.31% | -1138.63% | -23.70% | 0.09 | -1261.60 | 3.25 | 3.04 | 4.69 | -9117.00% | 3211.00% | -3553.00% | -351.80% | -2.53 | -855.05% | 0.00% | 0.00% | 329.11% | 0.61 | 0.81 | -53.31 | -34.45 |
| CYCN | Cyclerion Therapeutics, I… | $1.35 | 5.14M | — | +2,196,706% | — | — | -2.31 | 0.80 | 3.53 | -1.05 | — | 0.80 | 100.00% | -181.40% | -152.85% | -30.36% | -77.73% | -26.64% | 0.00 | — | 5.83 | 5.22 | 0.89 | -8654.00% | — | -7960.00% | -61.46% | -5.98 | -92.83% | 0.00% | 0.00% | 0.00% | -1.05 | -0.88 | 1.91 | -33.88 |
| KTTA | Pasithea Therapeutics Cor… | $0.88 | 6.56M | — | — | — | — | -0.09 | 0.09 | — | 0.41 | — | 0.21 | 0.00% | — | — | -72.83% | -189.89% | -65.93% | 0.00 | — | 6.58 | 6.18 | 0.51 | -246.00% | — | 345.00% | -1067.47% | -12.43 | -185.53% | 0.00% | 0.00% | 0.00% | 0.39 | 0.40 | — | -6.17 |
| PLRZ | Polyrizon Ltd. | $12.49 | 13.01M | — | — | — | — | -8.81 | 2.58 | — | -7.77 | — | 5.67 | 0.00% | — | — | -57.83% | -88.33% | -50.61% | 0.00 | -434.00 | 10.16 | 9.79 | 1.79 | — | — | 11359.00% | -8.43% | -4.39 | -77.82% | 0.00% | 0.00% | 20.20% | -8.49 | -9.64 | — | 29.76 |
| PMCB | PharmaCyte Biotech, Inc. | $0.69 | 4.69M | — | — | — | — | 0.26 | 0.16 | — | -0.24 | — | 0.16 | 0.00% | — | — | 67.08% | -34.09% | 53.28% | 0.00 | — | 7.68 | 6.60 | -0.49 | -27722.00% | — | 3843.00% | -36.94% | -1.02 | -23.19% | 14.01% | 3.70% | 324.43% | 1.71 | 2.51 | — | -0.52 |
| QNRX | Quoin Pharmaceuticals, Lt… | $8.37 | 4.92M | — | — | — | — | -0.16 | 0.16 | — | 1.34 | — | 0.17 | 0.00% | — | — | -121.13% | 192.82% | -64.60% | 0.00 | — | 3.57 | 3.36 | 0.38 | -8019.00% | — | -9.00% | -540.58% | -1.88 | 159.01% | 0.00% | 0.00% | 84.08% | 1.32 | 1.60 | — | -5.96 |
| RADX | Radiopharm Theranostics L… | $4.99 | 6.43M | +1,761% | — | — | — | — | 1.36 | 16.76 | -0.83 | — | -34.17 | 1.08% | -1050.63% | -1055.27% | 0.00% | -302.69% | 0.00% | 0.00 | -584.59 | 2.67 | 2.65 | 0.76 | -8533.00% | 111427.00% | 5950.00% | -60.17% | -2.45 | -290.58% | 0.00% | — | 17.31% | -0.83 | -0.87 | 8.75 | -2.59 |
| TCRT | Alaunos Therapeutics, Inc… | $3.19 | 7.12M | +18,244% | -80% | — | — | -0.55 | 1.26 | 259.40 | -0.32 | — | 1.26 | 100.00% | -48120.00% | -46790.00% | -111.80% | -790.80% | -84.93% | 0.00 | — | 3.98 | 1.58 | 0.23 | -8671.00% | 10000.00% | -8362.00% | -191.63% | -7.18 | -816.93% | 0.00% | 0.00% | 0.00% | -0.31 | -0.30 | 150.30 | -470.35 |
| XTLB | XTL Biopharmaceuticals Lt… | $0.76 | 1.04M | — | +76% | — | — | -2.05 | 0.39 | 4.66 | -1.18 | — | -1.34 | 0.67% | -481.60% | -227.72% | -26.83% | -83.03% | -18.71% | 0.03 | -25.26 | 0.61 | 0.56 | 0.25 | — | — | 13649.00% | -79.50% | -0.73 | -72.01% | 0.00% | 0.00% | 0.00% | -0.51 | -0.66 | 2.44 | -26.54 |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
- CEO
- Keith E. Murphy
- Employees
- 14
- Beta
- 1.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.74 ÷ $1.44) − 1 = -48.61% (DCF, example).